Alentis Therapeutics secures FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting squamous cancers

Alphamab Oncology and CSPC enter licensing agreement for Anti-HER2 bispecific ADC JSKN003

Enhertu receives priority review in the US for HER2-Low and HER2-Ultralow metastatic breast cancer patients...

EMA recommends approval of Mirvetuximab Soravtansine for marketing authorization